Biotech companies prepared for their IPO comeback. Drafted the roadshow. Polished the pitch deck. Rehearsed the line about how their pipeline will revolutionize oncology.
Then Pfizer showed up with a suitcase full of cash and bought them in the parking lot.
The problem is simple. Major drug patents expire later this decade. Big pharma needs new products. They can either spend fifteen years and forty billion dollars inventing something, or they can write a check to a company that already did the work. Turns out acquisition beats innovation when your Lipitor money runs out in 2028.
Biotech founders now face an exciting choice. Go public and let retail traders value your company based on a Reddit thread about mouse trials. Or sell to Bristol-Myers for three billion and let them figure out Phase III.
The IPO revival was supposed to happen. Bankers already spent the fees. CNBC booked the segments. Some venture capital guy named Trevor already updated his LinkedIn to Senior Managing Director of Life Sciences Capital Markets.
But every biotech CEO who planned to ring the opening bell just got a call from Merck's corporate development team. The offer is generous. The terms are clean. The alternative is explaining to public market investors why your burn rate is sixty million a quarter and your lead asset treats a disease that affects four hundred people.
IPO underwriters will tell you the window is opening. The market is ready. Investors are hungry for growth. They will not tell you that Johnson & Johnson is hungrier and has better credit terms.
Retail was really looking forward to buying biotech stocks at seventy dollars and watching them trade at fourteen by October. Big pharma ruined that for everyone by doing basic math.
Photo by Etactics Inc on Unsplash
Leave a Comment